osimertinib

1. 18:42
   x.com

   ☝🏼#ESMO26 Targeted therapies: toxicity is not just about the drug — context matters.
2. 18:06
   x.com

   🧬 Early ctDNA clearance tells us a lot about prognosis — but not necessarily which treatment to choose.
3. 15:49
   x.com

   Temab-A an ADC antiMET good activty in MET+ nonSq pretreted wt and EGFRm NSCLC. But: easy to test biomarker in daily practice? In EGFRm cohort higher activity if we add osimertinib
4. 15:07
   x.com

   Superb discussion by @LeXiuning at #ESMO26 on ctDNA-guided treatment selection in EGFRm NSCLC.
5. 15:06
   x.com

   Interesting integration of ctdna directed therapy in NSCLC
6. 15:00
   x.com

   #FLAURA2: Early ctDNA clearance didn’t identify who could forgo chemotherapy—PFS favored osimertinib + chemo regardless of week 1–2 clearance. Similar clearance rates, different ou
7. 14:49
   x.com

   🚨 ESMO 2026 | FLAURA2 ctDNA Analysis
8. 14:37
   x.com

   #ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 wer
9. 13:25
   x.com

   OncoAlert 4Sight Abstracts to be Presented at #ESMO26
10. 03:28
    x.com

    #ESMO2026 opened today in Madrid, and a big focus for EGFR+ #lungcancer is what happens when osimertinib stops working.

1. 00:50
   x.com

   @HHorinouchi's FLAURA2 summary carries the teaching point of the day: early plasma EGFRm clearance was prognostic but not predictive, so it shouldn't be the reason to add or skip c

1. 20:00
   clinicaltrials.gov

   Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

Heat now 55·Peak in the comparable set 90 (Oct 24 19:00)·Change over 24h in the comparable set +472%·Participants now 11

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.